Related Research Articles
Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus. In normal individuals, the immune system produces antibodies to foreign proteins (antigens) but not to human proteins (autoantigens). In some cases, antibodies to human antigens are produced; these are known as autoantibodies.
Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (DMARD), used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase.
Mixed connective tissue disease, commonly abbreviated as MCTD, is an autoimmune disease characterized by the presence of elevated blood levels of a specific autoantibody, now called anti-U1 ribonucleoprotein (RNP), together with a mix of symptoms of systemic lupus erythematosus (SLE), scleroderma, and polymyositis. The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., and the term was introduced by Leroy in 1980.
A nurse-led clinic is any outpatient clinic that is run or managed by registered nurses, usually nurse practitioners or Clinical Nurse Specialists in the UK. Nurse-led clinics have assumed distinct roles over the years, and examples exist within hospital outpatient departments, public health clinics and independent practice environments.
Ruplizumab is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia.
Interferon alpha-1 is a protein that in humans is encoded by the IFNA1 gene.
Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.
Lupus headache is a proposed, specific headache disorder in patients with systemic lupus erythematosus (SLE). Research shows that headache is a symptom commonly described by SLE patients —57% in one meta-analysis, ranging in different studies from 33% to 78%; of which migraine 31.7% and tension-type headache 23.5%. The existence of a special lupus headache is contested, although few high-quality studies are available to form definitive conclusions.
Blisibimod is a selective antagonist of B-cell activating factor, being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).
1000minds is a web application for decision-making and conjoint analysis supplied by 1000minds Ltd since 2003.
Lupus vasculitis is one of the secondary vasculitides that occurs in approximately 50% of patients with systemic lupus erythematosus (SLE).
Interleukin-38 (IL-38) is a member of the interleukin-1 (IL-1) family and the interleukin-36 (IL-36) subfamily. It is important for the inflammation and host defense. This cytokine is named IL-1F10 in humans and has similar three dimensional structure as IL-1 receptor antagonist (IL-1Ra). The organisation of IL-1F10 gene is conserved with other members of IL-1 family within chromosome 2q13. IL-38 is produced by mammalian cells may bind the IL-1 receptor type I. It is expressed in basal epithelia of skin, in proliferating B cells of the tonsil, in spleen and other tissues. This cytokine is playing important role in regulation of innate and adaptive immunity.
Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. SLE is a disease in which the immune system attacks the body's own cells and tissues. It can affect various organs or systems of the body. It is estimated that over half of people with SLE have neuropsychiatric involvement.
Daniel Jeffrey Wallace is an American rheumatologist, clinical professor, author, and fellow. Wallace has published 500 peer reviewed publications, 9 textbooks, and 28 book chapters on topics such as lupus, Sjögren syndrome, osteoarthritis, and fibromyalgia. He has the largest cohort of lupus patients in the United States (2000). A full professor of medicine, he is associate director of the Rheumatology Fellowship Program at Cedars-Sinai. His seminal contributions to research include being an author of the first paper to demonstrate vitamin D dysfunction and the importance of interleukin 6 in lupus, conducting the first large studies of apheresis in rheumatoid arthritis and lupus, and insights into the mechanisms of action of antimalarials. Wallace's research accomplishments also include conducting many clinical rheumatic disease trials, examining the role of microvascular angina and accelerated atherogenesis in lupus, and work on anti-telomere antibodies which have garnered him 6 papers in The New England Journal of Medicine. Wallace's monograph, The Lupus Book, has sold over 100,000 copies since 1995.
Robert George Lahita is an American physician, internist and rheumatologist, best known for his research into systemic lupus erythematosus. and other autoimmune diseases. He is the author of more than 16 books and 150 scientific publications in the field of autoimmunity and immuno-endocrinology and a media consultant on health-related issues. He currently serves as Director of the Institute of Autoimmune and Rheumatic Diseases at St. Joseph's Healthcare System, specializing in autoimmunity, rheumatology, and treatment of diseases of joints, muscle, bones and tendons including arthritis, back pain, muscle strains, common athletic injuries and collagen diseases.
Ianalumab is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.
Eldad Ben-Chetrit is a professor of Medicine, former Head of the Department of Medicine and former director of the Rheumatology unit (2009-2017) at the Hadassah-Hebrew University Medical Center in Jerusalem. He was a visiting professor at the Oklahoma Medical Research Foundation (1996), at the Biochemistry Department, Stanford University (2004), and at the Gaslini Children Hospital, University of Genoa, Italy, and the Tropical Medicine Clinic, University of Heidelberg, Germany (2016).
Efavaleukin alfa is an experimental drug that works as an interleukin-2 "mutein Fc fusion protein that preferentially binds the high-affinity IL-2 receptor alpha chain (CD25) to selectively promote Treg expansion". It is developed to treat systemic lupus erythematosus (SLE).
Josef Smolen is an Austrian rheumatologist and immunologist and professor emeritus at the Medical University of Vienna. Since 2018 he is chairman emeritus of the Department of Internal Medicine 3 and the Division of Rheumatology at the Medical University of Vienna and Vienna General Hospital and was the chairman of the 2nd Medical Department and Center for Diagnosis and Therapy of Rheumatic Diseases at the Lainz Hospital, now the Hietzing Clinic of the Vienna Health Association from 1989 to 2017.
References
- ↑ Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren; Dörner, Thomas; Urowitz, Murray; Hiepe, Falk (November 2017). "Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles". Annals of the Rheumatic Diseases. 76 (11): 1837–1844. doi:10.1136/annrheumdis-2017-211388. PMID 28780512. S2CID 3577398.
- ↑ Askanase, A.; Stach, C.; Brittain, C.; Stojan, G.; Furie, R. (1 June 2023). "Pos0115 Dapirolizumab Pegol Efficacy by Subgroups in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis of Phase 2 Clinical Trial Data". Annals of the Rheumatic Diseases. 82 (Suppl 1): 272–273. doi: 10.1136/annrheumdis-2023-eular.1991 . ISSN 0003-4967. S2CID 259786801.
- ↑ Furie, Richard A; Bruce, Ian N; Dörner, Thomas; Leon, Manuel Gustavo; Leszczyński, Piotr; Urowitz, Murray; Haier, Birgit; Jimenez, Teri; Brittain, Claire; Liu, Jiajun; Barbey, Catherine; Stach, Christian (6 May 2021). "Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus". Rheumatology. 60 (11): 5397–5407. doi:10.1093/rheumatology/keab381. ISSN 1462-0324. PMC 9194804 . PMID 33956056.